

## Rapid growth continues for Sisticmic

[Previous](#) | [Next](#)

Sisticmic, the stem cell and drug development technology company, has won a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise. The grant forms part of a £1M planned investment programme which, on the back of a very successful year for the company, will see Sisticmic more than double the size of its operation. To accommodate the expanded research team, the company is relocating to customised laboratories during the first half of 2012.



Jim Reid, Sisticmic's Chairman and CEO said, "Securing this support from Scottish Enterprise is a major achievement and shows great support by the Scottish Government for what we are doing. It adds to an already successful year for Sisticmic, a year which has seen us grow sales dramatically and develop our customer base in Europe, USA, Japan and Australia. We truly have become a global company during 2011 and we look forward to relocating in the first half of 2012 to allow this success and growth to continue. It is always an exciting opportunity to be on the lookout for new employees and we are ideally placed to recruit top talent. This type of grant support is crucial to help grow successful research focused biotech companies such as ours and we will ensure we make the most of it!"

"We work very closely with some of the world's leading stem cell and pharmaceutical companies and we need to continually review our operations to make sure that we have the best technology and services and we need a facility which suits our needs," explains Reid. "The world is waking-up to the incredible opportunities offered by stem cell technology. Opportunities which show great promise to prolong healthy life and Sisticmic is already a key part of this burgeoning worldwide industry."

Sisticmic's SistemRNA™, SistemQC™, SistemKB™ and SistemTOX™ products have brought new depth to miRNA analysis, which has been shown to add value to drug discovery, cell therapeutics and diagnostics. For 2012 the company looks forward to increased business and growing their client network around the world.

For further information on Sisticmic and Sisticmic miRNA analysis products, please visit: [www.sisticmic.co.uk](http://www.sisticmic.co.uk)

Regional Selective Assistance (RSA) is the main investment grant scheme in areas of Scotland designated for regional aid under European Community law. RSA funding is available to create or safeguard jobs for both Scottish owned businesses and inward investors. For further information visit the Scottish Development International website: <http://www.sdi.co.uk>

Already a member? [Log in](#)

**Interested? Require further information?**

Note. Your details will be referred to the company and they will provide you with more information regarding your enquiry directly

If you have not logged into the website then please enter your details below.

## About You

Prof  Dr  Mr  Mrs  Miss  Ms

First Name

Last Name

Email

## Send Information To

Organization

Organization Address

Zip / Postal Code

--Country--

Telephone Number

Job Title

Primary Specific Discipline

Work Field

Type of enquiry

Message

I am looking to purchase this product in:

One Month



Please upgrade to a [supported browser](#) to get a reCAPTCHA challenge.

[Why is this happening to me?](#)

Request Information

## Related Articles:

- [Growth at Sistic Ltd due to success of unique miRNA analytical approach](#)
- [Sistic highlights the need for better cell characterisation in regenerative medicine](#)
- [Cell characterisation experts Sistic join the Alliance for Regenerative Medicine](#)
- [Sistic presents the solution for broader stem cell therapy at AUSBiotech 2011](#)
- [Sistic to work with TiGenix on landmark EUR 5.9 million, FP7 European project aiming at developing an innovative rheumatoid arthritis cell therapy treatment product](#)
- [Sistic supports Talent Scotland](#)
- [Maximise the potential of your stem cell applications](#)
- [Sistic shares its views on the cell therapeutics industry](#)
- [Merck and Broad Institute Announce CRISPR License Framework to Encourage Innovation](#)
- [Olympus Europe and Cytosurge Partner to Enhance Pharma Drug Development and Single Cell Research](#)
- [Cytel and Axio Join Forces to Create an Industry Leader in Analytical Solutions for Drug Development](#)
- [New technology to revolutionise drug development](#)
- [Absolute Antibody Launches Mouse Bispecific Antibody Reagents](#)

- [Linum Labs announces Molecule, a software platform and marketplace to accelerate innovation in pharma](#)
- [Attana's Technology Applied to Develop more Efficient Processes in Drug Development](#)
- [MediSapiens to Support Terveystalo with Biobank Data Management and Analytics Solutions](#)
- [Live Webinar on Pharmaceutical Analysis using Raman Imaging on Thursday 27th September at 3:00 pm \(UK\)](#)
- [Axol Bioscience Launch Human iPSC-Derived Atrial Cardiomyocytes](#)
- [Eatris announces Novel Public-Private Collaboration for Imaging Method Development in Inflammatory Diseases](#)

Newsletter Sign up

Subscribe here



Subscribe to receive our newsletters for the latest news on new laboratory products, research, Industry news and more



Weekly Update | Separation Science | Microscopy & Image Analysis | Monthly Update

Popular this Month...

Our Top 10 most popular articles this month

Today's Picks...

---

Looking for a Supplier?

## Search by company or by product

Company Name:

Product:

[S E A R C H](#)

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

---

[Previous](#) | [Next](#)

[Back to top](#)